{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T21:23:58Z","timestamp":1787174638993,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016016","name":"Gilead UK and Ireland Corporate Contributions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jiac.2026.103047","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:49:48Z","timestamp":1785826188000},"page":"103047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Twenty-four month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: Real-world data from the BICSTaR Japan cohort"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3838-0961","authenticated-orcid":false,"given":"Dai","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6884-2134","authenticated-orcid":false,"given":"Katsuji","family":"Teruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yokomaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2800-2492","authenticated-orcid":false,"given":"Tomoyuki","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1213-0949","authenticated-orcid":false,"given":"Nao","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Ramroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marongiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Shirasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-2167","authenticated-orcid":false,"given":"Shinichi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2026.103047_bib1","article-title":"HIV and AIDS estimates","year":"2023","journal-title":"Country Factsheets: Japan"},{"key":"10.1016\/j.jiac.2026.103047_bib2","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2026.103047_bib3","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1097\/QAI.0000000000001258","article-title":"HIV and aging: demographic change in the Asia-Pacific region","volume":"74","author":"Puhr","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2026.103047_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/hiv.13460","article-title":"Long-term success for people living with HIV: a framework to guide practice","volume":"24","author":"Lazarus","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2026.103047_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/hiv.13206","article-title":"Comorbidities and co-medications among 28 089 people living with HIV: a nationwide cohort study from 2009 to 2019 in Japan","volume":"23","author":"Naito","year":"2022","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2026.103047_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.35772\/ghm.2021.01120","article-title":"AIDS at 40th: the progress of HIV treatment in Japan","volume":"4","author":"Oka","year":"2022","journal-title":"Glob Health Med"},{"key":"10.1016\/j.jiac.2026.103047_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jiac.2018.10.006","article-title":"Greater burden of chronic comorbidities and co-medications among people living with HIV versus people without HIV in Japan: a hospital claims database study","volume":"25","author":"Ruzicka","year":"2019","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.103047_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/PPA.S192735","article-title":"Adherence to HIV treatment regimens: systematic literature review and meta-analysis","volume":"13","author":"Altice","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jiac.2026.103047_bib9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","article-title":"Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries","volume":"17","author":"Cohen","year":"2020","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jiac.2026.103047_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society\u2013USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2026.103047_bib12","series-title":"EACS guidelines","year":"2023"},{"key":"10.1016\/j.jiac.2026.103047_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAI.0000000000002137","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial","volume":"82","author":"Kityo","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2026.103047_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hiv.13319","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565 years of age","volume":"24","author":"Maggiolo","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2026.103047_bib15","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2026.103047_bib16","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2026.103047_bib17","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","article-title":"Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus","volume":"73","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103047_bib18","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2026.103047_bib19","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2026.103047_bib20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/hiv.13386","article-title":"Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: a pooled analysis from three international phase III randomized trials","volume":"24","author":"Avihingsanon","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2026.103047_bib21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/hiv.13593","article-title":"Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: real-world insights from BICSTaR cohorts","volume":"25","author":"Esser","year":"2024","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2026.103047_bib22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jgar.2022.06.027","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice","volume":"30","author":"Armenia","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jiac.2026.103047_bib23","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.2147\/IDR.S331647","article-title":"Outcomes after switching to BIC\/FTC\/TAF in patients with virological failure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors: a real-world cohort study","volume":"14","author":"Chang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiac.2026.103047_bib24","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1097\/QAD.0000000000003311","article-title":"Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment experience patients","volume":"36","author":"Mic\u00e1n","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2026.103047_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac018","article-title":"Advanced HIV infection in treatment-naive individuals: effectiveness and persistence of recommended 3-drug regimens","volume":"9","author":"Mounzer","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2026.103047_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027330","article-title":"Real-world efficacy and safety of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in older people living with HIV","volume":"100","author":"Rolle","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jiac.2026.103047_bib27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.18683\/germs.2021.1286","article-title":"Treatment initiation or switch to BIC\/FTC\/TAF - real-world safety and efficacy data from two HIV centers in Romania","volume":"11","author":"S\u0103ndulescu","year":"2021","journal-title":"Germs"},{"key":"10.1016\/j.jiac.2026.103047_bib28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/hiv.13376","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in patients with genotypic NRTI resistance","volume":"24","author":"Shafran","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2026.103047_bib29","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/jac\/dkae081","article-title":"Long-term outcomes of bictegravir\/emtricitabine\/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort","volume":"79","author":"d'Arminio Monforte","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.103047_bib30","series-title":"Anti-HIV Treatment Guidelines","year":"2024"},{"key":"10.1016\/j.jiac.2026.103047_bib31","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jmii.2024.07.003","article-title":"Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in treatment-na\u00efve and treatment-experienced people with HIV: findings from the Asia cohort of the BICSTaR study","volume":"57","author":"Tseng","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jiac.2026.103047_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0313338","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in treatment-na\u00efve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort","volume":"20","author":"Yokomaku","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2026.103047_bib33","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort","volume":"26","author":"Trottier","year":"2025","journal-title":"HIV Res Clin Pract"},{"key":"10.1016\/j.jiac.2026.103047_bib34","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103047_bib35","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103047_bib36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103047_bib37","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2147\/PPA.S207908","article-title":"Treatment adherence and persistence among HIV-1 patients newly starting treatment","volume":"13","author":"Hines","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jiac.2026.103047_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-67837-6","article-title":"Relationship between adherence to bictegravir\/emtricitabine\/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis","volume":"14","author":"Taguchi","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiac.2026.103047_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/09540121.2018.1533232","article-title":"Non-persistence to antiretroviral therapy among adults receiving HIV medical care in the United States","volume":"31","author":"Nyaku","year":"2019","journal-title":"AIDS Care"},{"key":"10.1016\/j.jiac.2026.103047_bib40","series-title":"Biktarvy: summary of product characteristics","year":"2024"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:26:31Z","timestamp":1787171191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1341321X26001455"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103047","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twenty-four month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with HIV: Real-world data from the BICSTaR Japan cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103047"}}